Biotechnology

LEPU BIO

Lepu Biopharma Achieves First Full-Year Profit in 2025

LEPU BIO-B released FY2025 9 Months Earnings on March 25 (BJT), actual revenue HKD 760.81 M, actual EPS HKD 0.0893

LEPU BIO-B released FY2025 Q3 earnings on March 25, 2026 (BJT), with actual revenue of HKD 256.31 M and EPS of HKD 0.0667

LEPU BIO-B released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 260.73 M, actual EPS HKD 0.0678

LEPU BIO-B released FY2025 earnings on March 25 After-Market (BJT), actual revenue HKD 1.022 B (forecast HKD 723.23 M), actual EPS HKD 0.1627 (forecast HKD -0.0389)

Lepu Biologics Reports Profit of 261 Million RMB for FY 2025

LEPU BIO-B to release FY2025 earnings on March 25 After-Market (BJT), forecast revenue HKD 709.57 M, EPS HKD -0.0381

NMPA Approves Leple Biotech's Injection of Vebetoclimab for Marketing

Guotai Hexun First Covers Lepu Biopharma with an Overweight Rating

Lepu Biopharma's 自主研发 MRG006A completes first patient enrollment in Phase II clinical trial for late-stage hepatocellular carcinoma

LEPU BIO-B released FY2025 Q1 earnings on August 20 (BJT), actual revenue HKD 249.51 M, actual EPS HKD 0.0107

Chinese Innovative Pharma Companies First NewCo Transaction Led by Domestic Investors

LEPU BIO-B released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue HKD 0, actual EPS HKD 0

LEPU BIO-B released FY2025 Semi-Annual Earnings on August 20 After-Market (BJT), actual revenue HKD 504.5 M, actual EPS HKD 0.0216

Lepu Biopharma-B Reports First-Ever Profit in Semi-Annual Results

LEPU BIO-B FY2025 Semi-Annual Earnings Release on August 20, 2025 (BJT)

Lepu Biologics MRG004A Receives Breakthrough Therapy Designation

Lepu Biopharma Expected to Report Profit of 24 Million Yuan in H1, First Profitable Period

Lepu Biopharma-B Signs License Agreement with Excalipoint for TOPAbody Platform

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

02157

Lepu Biopharma Co. Ltd. has received approval from the Hong Kong Stock Exchange to exit the biotech marker regime after meeting the necessary market capitalization and revenue thresholds. This transition signifies the company's maturity, as it will no longer be identified as a Chapter 18A biotech issuer starting May 11, 2026. The stock code 2157 will remain unchanged, and existing trading arrangements will not be affected. This upgrade reflects Lepu Biopharma's growth and stability in the biopharmaceutical market.

Tip Ranks

Lepu Biopharma Exits Biotech Marker Regime After Meeting HKEX Mainboard Tests

513120

In a report released yesterday, from Huachuang Securities maintained a Buy rating on Lepu Biopharma Co. Ltd. Class H, with a price target of HK$8.10.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Lepu Biopharma Co. Ltd. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$8.10.

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huachuang Securities Keeps Their Buy Rating on Lepu Biopharma Co. Ltd. Class H (2157)

560600

159859

516500

159102

159849

512290

Lepu Biopharma (SEHK:2157) has reported a significant earnings turnaround, moving from a net loss to a net income of CNY 261.36 million for the full year 2025, with sales reaching CNY 934.87 million. The company's share price has surged, with a 30-day return of 40.09% and a year-to-date return of 23.49%. However, it trades at a high P/E ratio of 37.3x, which is considered overvalued compared to its estimated fair level of 3.2x. Investors are advised to weigh the optimism against potential risks as the company relies on a pipeline still in clinical trials.

Simplywall

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Assessing Lepu Biopharma’s Valuation After Earnings Turnaround And Share Price Surge

02609

06636

00100

Hong Kong stock market overview in the past hour Market sentiment seems to be gradually warming up amid recent fluctuations, especially with strong performances in the healthcare and technology sectors. Capital flows are clearly favoring small-cap stocks and emerging industries, with short-term enthusiasm rising, driving overall gains. BAYZED HEALTH's strong surge has attracted market attention, and other related stocks have also become active, creating a positive linkage effect. Overall, stocks with significant gains are mostly concentrated in the pharmaceutical and technology sectors, indicating investors' preference for these areas. The stock with the largest movement in the past hour, BAYZED HEALTH, surged 20.20%, becoming the market focus. The stock quickly rose in the early trading phase, attracting a large influx of capital, with short-term sentiment running high, driving subsequent buying. The market's optimistic expectations for its future development seem to provide strong support. Strong stocks 1. EXTREME VISION: up 15.63%, recent market attention on its technological innovations has increased, with noticeable capital inflow. 2. MINIMAX-W: up 15.33%, active short-term capital, with market sentiment high, driving rapid price increases. 3. FLOWING CLOUD: up 15.29%, performing well driven by technology stocks, attracting considerable short-term capital. 4. LEPU BIO-B: up 15.17%, strong performance in the pharmaceutical sector supports its stock price's continuous rise. 5. CIFI HOLD GP: up 15.15%, with optimistic expectations for its future performance, capital continues to flow in

HK Stock Alerts

BAYZED HEALTH

EXTREME VISION

MINIMAX-W

FLOWING CLOUD

CIFI HOLD GP

ONEROBOTICS

LEADS BIOLABS-B

LINGBAO GOLD

COSCO SHIP ENGY

TONGGUAN GOLD

Hong Kong Stock Movement Update: The medical technology sector rebounds strongly, BAYZED HEALTH surges 20% to lead the gains!

00799

01672

02291

02650

02477

00586

03320

02197

03888

IGG(00799) rose 20.88%, with a trading turnover 46.7 Million HKD, and a year-to-date fell 5.8%. ASCLETIS-B(01672) rose 12.67%, with a trading turnover 147.1 Million HKD, and a year-to-date rose 42.8%. SCIENTECH(02291) rose 11.13%, with a trading turnover 151.8 Million HKD, and a year-to-date fell 1.9%.

Top Gainers&Losers

ASCLETIS-B

SCIENTECH

ZHIDA TECH

WELLCELL HOLD

CONCH VENTURE

CHINARES PHARMA

CLOVER BIO-B

KINGSOFT

Top 10 HK Stock Gainers (3.26)

Hong Kong's biopharmaceutical sector saw significant stock gains amid market volatility, with XuanZhu Biopharma-Brising over 12%, Ascletis Pharmaincreasing by more than 7%, and both Lepu Biopharmaand XtalPi Holdingsclimbing over 6%. Akeso Biopharmaalso saw a rise of 5.5%. This trend indicates a positive outlook for the biopharmaceutical industry in Hong Kong's stock market.

CoinLive

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

XTALPI

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

AKESO

ChinaAMC SSE STAR Biology and Medicine ETF

First Trust NYSE Arca Biotech Index Fd

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

XUANZHUBIO-B

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility

LEPU BIO-B announced its full-year results for the year ending last December, with revenue of RMB 935 million, an increase of 154.2% year-on-year. It turned a loss into a profit of RMB 261 million, achieving profitability in its first year, compared to a loss of RMB 411 million in the same period last year; earnings per share were RMB 0.15. No dividend was declared. Under non-International Financial Reporting Standards measurement, LEPU BIO approached breakeven last year, recording an adjusted net loss of approximately RMB 30.6 million

AASTOCKS

"Performance" LEPU BIO turned a loss into a profit of 261 million RMB for the whole year, achieving profitability in its first year

Shanghai-based Excalipoint Therapeutics has launched with $68.7 million in financing and a portfolio of antibody drugs targeting cancer and autoimmune diseases. The startup focuses on T cell engagers, which are designed to enhance immune responses against tumors. Its lead drug is in early human testing for DLL3-expressing malignancies, with another targeting gastrointestinal tumors expected later this year. Excalipoint aims to address challenges in solid tumor treatments and has secured backing from notable investors, marking one of the largest seed rounds for a Chinese biotech startup.

biopharmadive

KETOP

Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers

Lepu Biopharma Co. Ltd. (HK:2157) has issued a profit alert, expecting a net profit of at least RMB200 million for the year ending December 31, 2025, a significant turnaround from a loss of RMB411 million in 2024. This improvement is attributed to strong sales of oncology products and increased licensing income. The company anticipates a one-off gain in 2025 due to a reclassification of an investment. Analysts currently rate the stock as a Hold with a price target of HK$4.50, advising caution until final results are confirmed.

Lepu Biopharma Signals 2025 Profit on Strong Oncology Sales and Licensing Gains

LEPU BIO-B (2157.HK) shows a clear bottom weak oscillation pattern in its daily chart, with the MACD dead cross failing to effectively repair, and the green bars slowly increasing, indicating that the technical rebound is hindered. The company's stock price has repeatedly attempted to rise above the short-term moving averages without success, and the main capital shows a heavy wait-and-see sentiment, lacking short-term hot spots to activate the market. The biotechnology sector as a whole has recently performed poorly, lacking systematic thematic drivers, and the willingness of external funds to flow in is low. 

In terms of fundamentals, LEPU BIO focuses on the biopharmaceutical field and has strong innovation capabilities, but is constrained by regulatory policies and market pressures, with its profit model not fully established, lacking strong stimulus terms in the short term. Recently, there has been a lack of significant R&D and industrial cooperation news, and the valuation is in a repeated bottom range. Technically, attention should be paid to the lower Bollinger Band and historical support levels on the daily chart; a breach may bring new round of adjustment pressure. 

It is recommended that investors adopt a defensive wait-and-see approach in the short term, closely monitor the capital flow in the sector and the progress of the company's new products, and wait for a volume breakout confirmation before participating in the oversold recovery. Without effective catalysts, it is only suitable for low-position testing and swing participation, with strict control over stop-loss levels. In the medium to long term, there will only be significant upside potential on the right side if industry regulation and the company's fundamentals improve simultaneously

Technical Forecast

Morning Trend | LEPU BIO-B shows weak fluctuations in the range, what to pay attention to in this subtle market window?

LEPU BIO(02157.HK)